Grant: Team Grant: CCNA Phase III: Nutrition and Metabolic Health in Aging
McGill University
$1,057,080.00
Effects of GLP1 agonist-induced weight loss on cerebral and blood markers of neurodegeneration in individuals with obesity and genetic risk for Alzheimer's disease.
FY 2024-25
Summary
Obesity in mid-life is a significant risk factor for dementia and Alzheimer's disease. However until recently there were very few safe and effective weight loss treatments available. This situation has changed in the last few years with the advent of a class of medications called GLP1 receptor agonists. These medications were originally developed to treat diabetes however it was realized that they could also cause significant weight loss in people without diabetes. We plan to recruit 120 individuals with obesity and genetic risk for Alzeimer's disease aged 30-55 and administer a medication called tirzepatide to them for one year. This is expected to cause a 15 to 20% loss in body weight and ameliorate metabolic measures. We will then use magnetic resonance imaging to see if weight loss is associated with concomitant changes in brain health. Participants will have extensive clinical evaluations. We will then be able to see if improvement in metabolism is associated with improvements in brain and cerebrovascular function and anatomy.
Department
Program
Team Grant: CCNA Phase III: Nutrition and Metabolic Health in Aging
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529582
Name
Dagher Alain
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Canadian Consortium on Neurodegeneration in Aging (CCNA) Phase III: Research Teams
Projecttitle
Effects of GLP1 agonist-induced weight loss on cerebral and blood markers of neurodegeneration in individuals with obesity and genetic risk for Alzheimer's disease.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$1,057,080
Cihrequipment2
$0
Programname2
Team Grant: CCNA Phase III: Nutrition and Metabolic Health in Aging
Keyworddelim
Alzheimer'S Disease; Brain Health; Cerebrovascular Disease; Dementia; Magnetic Resonance Imaging; Metabolic Syndrome; Neurodegeneration; Obesity; Weight Loss
Abstract
Obesity in mid-life is a significant risk factor for dementia and Alzheimer's disease. However until recently there were very few safe and effective weight loss treatments available. This situation has changed in the last few years with the advent of a class of medications called GLP1 receptor agonists. These medications were originally developed to treat diabetes however it was realized that they could also cause significant weight loss in people without diabetes. We plan to recruit 120 individuals with obesity and genetic risk for Alzeimer's disease aged 30-55 and administer a medication called tirzepatide to them for one year. This is expected to cause a 15 to 20% loss in body weight and ameliorate metabolic measures. We will then use magnetic resonance imaging to see if weight loss is associated with concomitant changes in brain health. Participants will have extensive clinical evaluations. We will then be able to see if improvement in metabolism is associated with improvements in brain and cerebrovascular function and anatomy.
Competitiondate
202412
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Dagher, Alain
Approvedterm
4 ans 0 mois
Cihrcontribution2
INMD~ $736,560~ $0~MI #2~ $245,520~ $0~SPOR~ $75,000~ $0~
